Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,321 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: docetaxel Clear all
Completed Phase 1 Interventional

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

NCT01041235
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions
ATI-1123 (active drug = docetaxel)
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

NCT00014352
View directory record Official record
Conditions
Prostate Cancer, Thromboembolism
Interventions
docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 31, 2026, 11:55 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

NCT00428714
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

NCT00177242
View directory record Official record
Conditions
Cancer
Interventions
Gefitinib
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

NCT00193323
View directory record Official record
Conditions
Lung Cancer
Interventions
Docetaxel, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 1 Interventional

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

NCT05062980
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
quaratusugene ozeplasmid, pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice
Biological · Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Tampa, Florida • New Orleans, Louisiana • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 1 Interventional

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

NCT01911325
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Buparlisib, Buparlisib matching placebo, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel in Treating Patients With Relapsed Prostate Cancer

NCT00482274
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

NCT00148122
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

NCT02516670
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
Dietary Supplement · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck

NCT01275183
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
raltegravir and cisplatin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00356122
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00637897
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, ixabepilone, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, paricalcitol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil

NCT00400205
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oral Cancer
Interventions
Docetaxel, Cisplatin, 5-fluorouracil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780
View directory record Official record
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
54
States / cities
Anaheim, California • Duarte, California • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

NCT00148070
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Erythromycin Breath Test (ERMBT)
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

NCT00707473
View directory record Official record
Conditions
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Interventions
Carboplatin, Chemoradiotherapy, Cisplatin, Definitive Surgical Resection, Docetaxel, Fluorouracil, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
17 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Fulvestrant, Standard Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
55
States / cities
Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 31, 2026, 11:55 AM EDT
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

NCT00600496
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions
AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 31, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504
View directory record Official record
Conditions
Advanced Solid Tumors, Non Small Cell Lung Cancer
Interventions
sunitinib, docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2008 · Synced Oct 31, 2026, 11:55 AM EDT